Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one

@article{Tikhonovich2017NonsteroidAT,
  title={Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one},
  author={Marina V. Tikhonovich and A. Erdiakov and S. Gavrilova},
  journal={International Ophthalmology},
  year={2017},
  volume={38},
  pages={1365-1378}
}
PurposeThis study proves the possibility of targeted use of the nonsteroidal anti-inflammatory drug lornoxicam to prevent the development of proliferative vitreoretinopathy (PVR). Triamcinolone acetonide (TA) was selected as a reference substance.MethodsWistar rats (N = 400) were used. PVR was modeled by intravitreal injection of dispase or concanavalin A. Lornoxicam or TA intravitreal administration was performed 20 min later. On the second and the third day, drugs were administrated systemic… Expand
6 Citations

References

SHOWING 1-10 OF 44 REFERENCES
Inflammation-Mediated Retinal Edema in the Rabbit Is Inhibited by Topical Nepafenac
  • 71
  • PDF
A new model of proliferative vitreoretinopathy.
  • 57
  • PDF
Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences
  • 135
Expression of cyclooxygenases and trophic and growth factors in epiretinal membranes at late stages of proliferative vitreoretinopathy
  • 4
Retinal toxicity of intravitreal triamcinolone acetonide at high doses in the rabbit.
  • 48
A mouse model of proliferative vitreoretinopathy induced by dispase.
  • 40
Evaluation of vitreous clearance and potential retinal toxicity of intravitreal lornoxicam (xefo).
  • V. Diakonis, A. Tsourdou, +5 authors M. Tsilimbaris
  • Medicine
  • Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • 2013
  • 6
...
1
2
3
4
5
...